Selected studies of monoclonal antibodies in lymphoma
| mAB . | Target . | Study phase . | Patient population . | Outcome(s) . |
|---|---|---|---|---|
| Obinutuzumab | CD20 | III3 | Previously untreated FL | 3-y PFS: 80.0% (obinutuzumab-based chemotherapy) vs 73.3% (rituximab-based chemotherapy) |
| ORR: 88.5% vs 86.9% | ||||
| Grade 3-5 AEs: 74.6% vs 67.8% | ||||
| SAEs: 46.1% vs 39.9% | ||||
| III4 | Indolent NHL refractory to rituximab | Median PFS: not reached (obinutuzumab plus bendamustine) vs 14.9 mo (bendamustine monotherapy) | ||
| Grade 3-5 AEs: 68% vs 62% | ||||
| SAEs: 38% vs 33% | ||||
| Tafasitamab | CD19 | IIa7 | R/R NHL | Tafasitamab monotherapy |
| ORR: 26% (DLBCL), 29% (FL), 27% (other) | ||||
| AEs: IRR (12%), neutropenia (12%) | ||||
| II8 | R/R DLBCL | Tafasitamab with lenalidomide | ||
| ORR of 54%, CR rate of 32%, PR rate of 22% | ||||
| Treatment-related SAEs: infections (10%), neutropenic fever (5%) | ||||
| Magrolimab | CD47 | Ib/II9 | R/R NHL | Magrolimab with rituximab |
| TRAEs: chills (41%), headache (41%), anemia (41%), IRR (36%) | ||||
| ORR of 50%, CR rate of 36% | ||||
| Mogamulizumab | CCR4 | III10 | R/R CTCL | Median PFS: 7.7 (mogamulizumab) vs 3.1 mo (vorinostat) |
| Grade 3-4 AEs: 41% vs 41% |
| mAB . | Target . | Study phase . | Patient population . | Outcome(s) . |
|---|---|---|---|---|
| Obinutuzumab | CD20 | III3 | Previously untreated FL | 3-y PFS: 80.0% (obinutuzumab-based chemotherapy) vs 73.3% (rituximab-based chemotherapy) |
| ORR: 88.5% vs 86.9% | ||||
| Grade 3-5 AEs: 74.6% vs 67.8% | ||||
| SAEs: 46.1% vs 39.9% | ||||
| III4 | Indolent NHL refractory to rituximab | Median PFS: not reached (obinutuzumab plus bendamustine) vs 14.9 mo (bendamustine monotherapy) | ||
| Grade 3-5 AEs: 68% vs 62% | ||||
| SAEs: 38% vs 33% | ||||
| Tafasitamab | CD19 | IIa7 | R/R NHL | Tafasitamab monotherapy |
| ORR: 26% (DLBCL), 29% (FL), 27% (other) | ||||
| AEs: IRR (12%), neutropenia (12%) | ||||
| II8 | R/R DLBCL | Tafasitamab with lenalidomide | ||
| ORR of 54%, CR rate of 32%, PR rate of 22% | ||||
| Treatment-related SAEs: infections (10%), neutropenic fever (5%) | ||||
| Magrolimab | CD47 | Ib/II9 | R/R NHL | Magrolimab with rituximab |
| TRAEs: chills (41%), headache (41%), anemia (41%), IRR (36%) | ||||
| ORR of 50%, CR rate of 36% | ||||
| Mogamulizumab | CCR4 | III10 | R/R CTCL | Median PFS: 7.7 (mogamulizumab) vs 3.1 mo (vorinostat) |
| Grade 3-4 AEs: 41% vs 41% |
AEs, adverse events; CR, complete response; CTCL, cutaneous T-cell lymphoma; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; IRR, infusion-related reaction; mAB, monoclonal antibody; NHL, non-Hodgkin lymphoma; ORR, overall response rate; PFS, progression-free survival; PR, partial response; SAEs, serious adverse events; TRAEs, treatment-related adverse events.